-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2023-507187-39-00
5
2023-03-23
High-Risk Non-muscle-invasive Bladder Cancer
-
2024-510818-33-00
5
2023-01-24
Chronic Spontaneous Urticaria
-
2023-504194-21-00
5
2022-09-13
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2024-512347-23-00
6
2022-08-22
Oral contraception
-
2023-505974-14-00
5
2022-06-23
Multiple Sclerosis (MS)
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2024-515092-36-00
5
2022-02-14
Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-509372-41-00
5
2022-01-30
Multiple Sclerosis
-
2023-507974-42-00
4
2021-12-01
Moderate to Severe Ulcerative Colitis
-
2023-506241-30-00
5
2021-11-30
Advanced Colorectal Cancer with KRAS G12C Mutation
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-510307-22-00
1
2021-09-24
Advanced head and neck cancer
-
2024-511285-37-00
11
2021-08-31
Hereditary Angioedema
-
2023-504734-21-00
5
2021-08-30
Psoriatic arthritis (PsA)
-
2022-502856-29-00
7
2021-07-27
Advanced Solid Tumors
-
2024-513527-17-00
4
2021-06-07
Multiple Sclerosis
-
2022-502122-41-00
5
2021-05-11
Clear cell renal cancer
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer